<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="other"><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS Med</journal-id><journal-id journal-id-type="publisher-id">pmed</journal-id><journal-title>PLoS Medicine</journal-title><issn pub-type="ppub">1549-1277</issn><issn pub-type="epub">1549-1676</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.1371/journal.pmed.0040164</article-id><article-id pub-id-type="publisher-id">07-PLME-C-0153</article-id><article-categories><subj-group subj-group-type="heading"><subject>Correspondence</subject></subj-group><subj-group subj-group-type="Discipline"><subject>Gastroenterology and Hepatology</subject><subject>Genetics and Genomics</subject><subject>Oncology</subject></subj-group></article-categories><title-group><article-title><italic>Palladin</italic> Mutation Causes Familial Pancreatic Cancer: Absence in European Families</article-title><alt-title alt-title-type="running-head">Correspondence</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Slater</surname><given-names>Emily</given-names></name></contrib><contrib contrib-type="author"><name><surname>Amrillaeva</surname><given-names>Vera</given-names></name></contrib><contrib contrib-type="author"><name><surname>Fendrich</surname><given-names>Volker</given-names></name></contrib><contrib contrib-type="author"><name><surname>Bartsch</surname><given-names>Detlef</given-names></name></contrib><contrib contrib-type="author"><name><surname>Earl</surname><given-names>Julie</given-names></name></contrib><contrib contrib-type="author"><name><surname>Vitone</surname><given-names>Louis J</given-names></name></contrib><contrib contrib-type="author"><name><surname>Neoptolemos</surname><given-names>John P</given-names></name></contrib><contrib contrib-type="author"><name><surname>Greenhalf</surname><given-names>William</given-names></name></contrib></contrib-group><pub-date pub-type="ppub"><month>4</month><year>2007</year></pub-date><pub-date pub-type="epub"><day>24</day><month>4</month><year>2007</year></pub-date><volume>4</volume><issue>4</issue><elocation-id>e164</elocation-id><copyright-statement><bold>Copyright:</bold> &#x000a9; 2007 Slater et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</copyright-statement><copyright-year>2007</copyright-year><related-article related-article-type="companion" vol="4" page="e516" id="N0x8cbd880N0x9cf9f28" ext-link-type="pmc"><article-title><italic>Palladin</italic> Mutation Causes Familial Pancreatic Cancer and Suggests a New Cancer Mechanism</article-title></related-article><counts><page-count count="1"/></counts><custom-meta-wrap><custom-meta><meta-name>citation</meta-name><meta-value><bold>Citation:</bold> Slater E, Amrillaeva V, Fendrich V, Bartsch D, Earl J, et al. (2007) Palladin mutation causes familial pancreatic cancer: Absence in European families. PLoS Med 4(4): e164. doi: <ext-link ext-link-type="doi" xlink:href="10.1371/journal.pmed.0040164">10.1371/journal.pmed.0040164</ext-link></meta-value></custom-meta></custom-meta-wrap></article-meta></front><body><p>We read with interest the article published in <italic>PLoS Medicine</italic> by Pogue-Geile et al. &#x0005b;<xref ref-type="bibr" rid="pmed-0040164-b001">1</xref>&#x0005d; reporting an apparent mutation in the KIAA0992 splice variant of the <italic>palladin</italic> gene in a family previously reported to have a high incidence of pancreatic cancer. Pogue-Geile and others had previously established that the 4q32&#x02013;34 locus segregated with pancreatic cancer in this family by screening for pre-neoplastic lesions, which could then be used as a marker for mutation carriers &#x0005b;<xref ref-type="bibr" rid="pmed-0040164-b002">2</xref>&#x0005d;. In the <italic>PLoS Medicine</italic> paper the authors show that the mutation in <italic>palladin</italic> is on the 4q32&#x02013;34 haplotype that segregates with the disease. The European Registry of Hereditary Pancreatitis and Familial Pancreatic Cancer (EUROPAC) and the German National Case Collection for Familial Pancreatic Cancer (FaPaCa) have recently shown that a mutation on 4q32&#x02013;34 is unlikely to explain pancreatic cancer in a majority of our European families, but we did not rule out segregation with the disease in a minority of families &#x0005b;<xref ref-type="bibr" rid="pmed-0040164-b003">3</xref>&#x0005d;.</p><p>Naturally we were keen to establish if the mutation seen in Family X from America was seen in any of our families, and so we have sequenced the locus in 74 individuals who were either affected by pancreatic cancer or who are obligate carriers (assuming autosomal dominant inheritance) of the disease mutation (in 74 families). We have also sequenced the locus in 14 affected individuals from 14 families with familial multiple mole melanoma with cases of pancreatic cancer (FAMMM-PC) &#x0005b;<xref ref-type="bibr" rid="pmed-0040164-b004">4</xref>&#x0005d; and nine sporadic pancreatic cancer patients of less than 50 years of age. We did not identify the mutation in any of the individuals, neither as a heterozygote or a homozygote.</p><p>This does not of course mean that other mutations in coding or non-coding regions of this variant of <italic>palladin</italic> or other variants are absent from European families. However, it is noteworthy that the phenotype of Family X is significantly different from the phenotype common to the families on the EUROPAC/FaPaCa registries. In particular, the incidence of diabetes in our families is relatively low, except where the diabetes is a direct consequence of development of cancer &#x0005b;<xref ref-type="bibr" rid="pmed-0040164-b003">3</xref>&#x0005d;. This presentation contrasts strongly with the family harbouring the <italic>palladin</italic> mutation &#x0005b;<xref ref-type="bibr" rid="pmed-0040164-b001">1</xref>,<xref ref-type="bibr" rid="pmed-0040164-b002">2</xref>&#x0005d;, where diabetes was common. It is possible that Family X (and the association with <italic>palladin</italic> mutation) is not typical of the familial pancreatic cancer syndrome.</p></body><back><ref-list><title>References</title><ref id="pmed-0040164-b001"><citation citation-type="journal"><person-group><name><surname>Pogue-Geile</surname><given-names>KL</given-names></name><name><surname>Chen</surname><given-names>R</given-names></name><name><surname>Bronner</surname><given-names>MP</given-names></name><name><surname>Crnogorac-Jurcevic</surname><given-names>T</given-names></name><name><surname>Moyes</surname><given-names>KW</given-names></name><etal/></person-group><year>2006</year><article-title><italic>Palladin</italic> mutation causes familial pancreatic cancer and suggests a new cancer mechanism</article-title><source>PLoS Med</source><volume>3</volume><fpage>e516</fpage><comment>doi: <ext-link ext-link-type="doi" xlink:href="10.1371/journal.pmed.0030516">10.1371/journal.pmed.0030516</ext-link></comment><pub-id pub-id-type="pmid">17194196</pub-id></citation></ref><ref id="pmed-0040164-b002"><citation citation-type="journal"><person-group><name><surname>Eberle</surname><given-names>MA</given-names></name><name><surname>Pfutzer</surname><given-names>R</given-names></name><name><surname>Pogue-Geile</surname><given-names>KL</given-names></name><name><surname>Bronner</surname><given-names>MP</given-names></name><name><surname>Crispin</surname><given-names>D</given-names></name><etal/></person-group><year>2002</year><article-title>A new susceptibility locus for autosomal dominant pancreatic cancer maps to chromosome 4q32-34</article-title><source>Am J Hum Genet</source><volume>70</volume><fpage>1044</fpage><lpage>1048</lpage><pub-id pub-id-type="pmid">11870593</pub-id></citation></ref><ref id="pmed-0040164-b003"><citation citation-type="journal"><person-group><name><surname>Earl</surname><given-names>J</given-names></name><name><surname>Yan</surname><given-names>L</given-names></name><name><surname>Vitone</surname><given-names>LJ</given-names></name><name><surname>Risk</surname><given-names>J</given-names></name><name><surname>Kemp</surname><given-names>SJ</given-names></name><etal/></person-group><year>2006</year><article-title>Evaluation of the 4q32-34 locus in European familial pancreatic cancer</article-title><source>Cancer Epidemiol Biomarkers Prev</source><volume>15</volume><fpage>1948</fpage><lpage>1955</lpage><pub-id pub-id-type="pmid">17035404</pub-id></citation></ref><ref id="pmed-0040164-b004"><citation citation-type="journal"><person-group><name><surname>Lynch</surname><given-names>HT</given-names></name><name><surname>Brand</surname><given-names>RE</given-names></name><name><surname>Hogg</surname><given-names>D</given-names></name><name><surname>Deters</surname><given-names>CA</given-names></name><name><surname>Fusaro</surname><given-names>RM</given-names></name><etal/></person-group><year>2002</year><article-title>Phenotypic variation in eight extended CDKN2A germline mutation familial atypical multiple mole melanoma-pancreatic carcinoma-prone families: The familial atypical mole melanoma-pancreatic carcinoma syndrome</article-title><source>Cancer</source><volume>94</volume><fpage>84</fpage><lpage>96</lpage><pub-id pub-id-type="pmid">11815963</pub-id></citation></ref></ref-list><fn-group><fn id="n3" fn-type="current-aff"><p>Detlef Bartsch, German National Case Collection for Familial Pancreatic Cancer (FaPaCa) St&#x000e4;dtische Kliniken Bielefeld-Mitte and The Philipps-University Marburg Marburg, Germany</p></fn><fn id="n4" fn-type="current-aff"><p>William Greenhalf (<email>greenhaf&#x00040;liv.ac.uk</email>)</p></fn><fn id="n5" fn-type="current-aff"><p>William Greenhalf, European Registries of Familial Pancreatic Cancer (EUROPAC) Liverpool, United Kingdom</p></fn><fn id="n1" fn-type="financial-disclosure"><p><bold>Funding:</bold> The authors received no specific funding for this article.</p></fn><fn id="n2" fn-type="conflict"><p><bold>Competing Interests:</bold> The authors have declared that no competing interests exist.</p></fn></fn-group></back></article> 